Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
Phase 2/3 randomized, parallel group, 2-arm study (treatment vs. control), investigating the
efficacy and safety of intravenous administration of anakinra, an interleukin 1 receptor
antagonist ( IL-1), added to standard treatment, compared to standard treatment alone, to
reduce hyperinflammation and respiratory distress in patients with SARS-CoV-2 infection.